Sphingomonas paucimobilis bloodstream infections associated with contaminated intravenous fentanyl

Emerging Infectious Diseases

Volumn 15, Issue 1, 2009, Pages 12-18

  Maragakis, Lisa L ^a   Chaiwarith, Romanee ^b   Srinivasan, Arjun ^c   Torriani, Francesca J ^d   Avdic, Edina ^e   Lee, Andrew ^a   Ross, Tracy R ^e   Carroll, Karen C ^a   Perl, Trish M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; FENTANYL;

ADULT; AGED; ARTICLE; BACTEREMIA; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD SAMPLING; BLOODSTREAM INFECTION; CATHETER REMOVAL; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETERIZATION; CLINICAL ARTICLE; CLINICAL PHARMACY; DRUG CONTAMINATION; DRUG CONTROL; FEMALE; HUMAN; KIDNEY FAILURE; MALE; PULSED FIELD GEL ELECTROPHORESIS; QUALITY CONTROL; RASH; SPHINGOMONAS PAUCIMOBILIS; UNITED STATES; WARD;

ADULT; AGED; ANALGESICS, OPIOID; BACTEREMIA; BLOOD; CULTURE MEDIA; DRUG CONTAMINATION; ELECTROPHORESIS, GEL, PULSED-FIELD; FEMALE; FENTANYL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MARYLAND; MIDDLE AGED; SPHINGOMONAS;

EID: 58849117699     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1501.081054     Document Type: Article

References (30)

1. US Food and Drug Administration. Guidance for FDA staff and industry compliance policy guides manual; section 460.200; pharmacy compounding; 2002 [cited 2008 Mar 28]. Available from http://www.fda.gov/OHRMS/DOCKETS/98fr/02D- 0242-gdl0001.pdf
2. Pegues DA. Improving and enforcing compounding pharmacy practices to protect patients. Clin Infect Dis. 2006;43:838-40. DOI: 10.1086/507341
3. Sunenshine RH, Tan ET, Terashita DM, Jensen BJ, Kacica MA, Sickbert-Bennett EE, et al. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy. Clin Infect Dis. 2007;45:527-33. DOI: 10.1086/520664
4. Civen R, Vugia DJ, Alexander R, Brunner W, Taylor S, Parris N, et al. Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy. Clin Infect Dis. 2006;43:831-7. DOI: 10.1086/507336
5. Perz JF, Craig AS, Stratton CW, Bodner SJ, Phillips WE Jr, Schaffner W. Pseudomonas putida septicemia in a special care nursery due to contaminated flush solutions prepared in a hospital pharmacy. J Clin Microbiol. 2005;43:5316-8. DOI: 10.1128/JCM.43.10.5316-5318.2005
6. Held MR, Begier EM, Beardsley DS, Browne FA, Martinello RA, Baltimore RS, et al. Life-threatening sepsis caused by Burkholderia cepacia from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state. Pediatrics. 2006;118:e212-5. DOI: 10.1542/peds.2005-2617
7. Patel PR, Larson AK, Castel AD, Ganova-Raeva LM, Myers RA, Roup BJ, et al. Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. JAMA. 2006;296:2005-11. DOI: 10.1001/jama.296.16. 2005
8. Centers for Disease Control and Prevention. Pseudomonas bloodstream infections associated with a heparin/saline flush - Missouri, New York, Texas, and Michigan, 2004-2005. MMWR Morb Mortal Wkly Rep. 2005;54:269-72.
9. Centers for Disease Control and Prevention. Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy - United States, July-Nov 2002. MMWR Morb Mortal Wkly Rep. 2002;51:1109-12.
10. Centers for Disease Control and Prevention. Update: delayed onset Pseudomonas fluorescens bloodstream infections after exposure to contaminated heparin flush - Michigan and South Dakota, 2005-2006. MMWR Morb Mortal Wkly Rep. 2006;55:961-3.
11. Hsueh PR, Teng LJ, Yang PC, Chen YC, Pan HJ, Ho SW, et al. Nosocomial infections caused by Sphingomonas paucimobilis: clinical features and microbiological characteristics. Clin Infect Dis. 1998;26:676-81. DOI: 10.1086/514595
12. Adams WE, Habib M, Berrington A, Koerner R, Steel DH. Postoperative endophthalmitis caused by Sphingomonas paucimobilis. J Cataract Refract Surg. 2006;32:1238-40. DOI: 10.1016/j.jcrs.2006.01.094
13. Kilic A, Senses Z, Kurekci AE, Aydogan H, Sener K, Kismet E, et al. Nosocomial outbreak of Sphingomonas paucimobilis bacteremia in a hemato/oncology unit. Jpn J Infect Dis. 2007;60:394-6.
14. Perola O, Nousiainen T, Suomalainen S, Aukee S, Karkkainen UM, Kauppinen J, et al. Recurrent Sphingomonas paucimobilis bacteraemia associated with a multi-bacterial water-borne epidemic among neutropenic patients. J Hosp Infect. 2002;50:196-201. DOI: 10.1053/jhin.2001.1163
15. Lemaitre D, Elaichouni A, Hundhausen M, Claeys G, Vanhaesebrouck P, Vaneechoutte M, et al. Tracheal colonization with Sphingomonas paucimobilis in mechanically ventilated neonates due to contaminated ventilator temperature probes. J Hosp Infect. 1996;32:199-206. DOI: 10.1016/S0195-6701(96)90146-2
16. Tenover FC, Arbeit RD, Goering RV. How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Molecular Typing Working Group of the Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol. 1997;18:426-39.
17. US Food and Drug Administration. FDA regulation of compounded drugs; 2008 [cited 2008 May 15]. Available from http://www.fda.gov/cder/pharmcomp/default. htm
18. Galson SK. Statement before the Senate committee on health, education, labor and pensions hearing on "federal and state role in pharmacy compounding and reconstitution: exploring the right mix to protect patients"; 2003 [cited 2008 Mar 28]. Available from http://www.fda.gov/ola/ 2003/pharmacycompound1023.html
19. US Food and Drug Administration. Guidance for industry; sterile drug products produced by aseptic processing - current good manufacturing practice; 2004 [cited 2008 Apr 2]. Available from http://www.fda.gov/cder/guidance/ 5882fnl.pdf
20. Western States Medical Center v. Shalala, 238 F.3d 1090 (9th Cir. 2001).
21. Thompson v. Western States Medical Center, 535 U.S. 357 (2002).
22. Harteker LR. Federal court strikes down compounding regulations. Am J Health Syst Pharm. 2001;58:638,640,643.
23. American Society of Health-System Pharmacists. ASHP guidelines on quality assurance for pharmacy-prepared sterile products. Am J Health Syst Pharm. 2000; 57:1150-69.
24. United States Pharmacopeia. Guidebook to pharmaceutical compounding - sterile preparations. Rockville (MD): The Pharmacopeia; 2008 [cited 2008 20 Nov]. Available from http://www.usp.org/products/797Guidebook
25. Kastango ES, Bradshaw BD. United States Pharmocopeia chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy. Am J Health Syst Pharm. 2004;61:1928-38.
26. Morris AM, Schneider PJ, Pedersen CA, Mirtallo JM. National survey of quality assurance activities for pharmacy-compounded sterile preparations. Am J Health Syst Pharm. 2003;60:2567-76.
27. Candy TA, Schneider PJ, Pedersen CA. Impact of United States Pharmacopeia chapter 797: results of a national survey. Am J Health Syst Pharm. 2006;63:1336-43. DOI: 10.2146/ajhp050447
28. US Food and Drug Administration. Report: limited FDA survey of compounded drug products 2003. [cited 2008 Mar 28]. Available from http://www.fda.gov/ cder/pharmcomp/survey.htm
29. Schweitzer SO. Trying times at the FDA ? the challenge of ensuring the safety of imported pharmaceuticals. N Engl J Med. 2008;358:1773-7. DOI: 10.1056/NEJMp0802041
30. Wood AJ. Playing "kick the FDA" - risk-free to players but hazardous to public health. N Engl J Med. 2008;358:1774-5. DOI: 10.1056/NEJMp0802227